Chao Huang

Mr. Chao Huang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in ACS Omega
Verified
Journal Article
Closed access
CHChao Huang
Chao Huang
TWTian Wen
Tian Wen
FSFeng-Juan Shi
Feng-Juan Shi
XZXiao-Yan Zeng
Xiao-Yan Zeng
YJYong-Jun Jiao
Yong-Jun Jiao

1 October 2016 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
LSLina Song
Lina Song
CHChao Huang
Chao Huang
WZWei Zhang
Wei Zhang
MMMing Ma
Ming Ma
ZCZhongwen Chen
Zhongwen Chen
YZYu Zhang
Yu Zhang

29 October 2019 in The Analyst
Verified
Journal Article
Closed access
PDF file
TLTian Lu
Tian Lu
KZKai-Di Zhu
Kai-Di Zhu
CHChao Huang
Chao Huang
TWTian Wen
Tian Wen
YJYong-Jun Jiao
Yong-Jun Jiao
Shou-Nian DingShou-Nian Ding
Shou-Nian Ding
Two types of lateral flow immunochromatographic test strips (LFITS) using gold nanoparticles and fluorescent CdTe quantum dots (QDs) as signal labels, respectively, were developed for Shiga toxin type II (STX2) assays. Under optimal conditions, the corresponding visual detection limits were 25 ng mL−1 and 5 ng mL−1, respectively. The test results of gold based LFITS can be recognized directly by the naked eye, whereas the visualized results of CdTe QDs based LFITS can be observed by the aid of a UV lamp. Both assays showed good specificity and stability. The inexpensive LFITS were promising for the rapid clinical detection of STX2.

10 January 2019 in Luminescence
Verified
Journal Article
Closed access
PDF file
CHChao Huang
Chao Huang
QWQiaozhen Wei
Qiaozhen Wei
QHQiushi Hu
Qiushi Hu
TWTian Wen
Tian Wen
LXLei Xue
Lei Xue
LZLei Zhou
Lei Zhou

4 August 2015 in Viruses
Verified
Journal Article
Open access
PDF file
LZLi Zhang
Li Zhang
JLJing Lu
Jing Lu
YCYin Chen
Yin Chen
FSFengjuan Shi
Fengjuan Shi
YHYu Huiyan
Yu Huiyan
YHYuemei Hu
Yuemei Hu
In April 2013, human infections with a novel avian influenza (H7N9) virus emerged in China. It has caused serious concerns for public health throughout the world. However, there is presently no effective treatment, and an A (H7N9) H7 subtype influenza vaccine is not available. Vaccination with virus-like particles (VLPs) has showed considerable promise for many other subtype influenza viruses. To produce H7N9 VLPs, full length, unmodified hemagglutinin (HA), neuraminidase (NA), and matrix1 (M1) genes from the A/Wuxi/1/2013(H7N9) were cloned into a pCDNA5.1 FRT vector. By co-transfection, VLPs containing HA, NA, and M1 were secreted by 293T cells. VLPs were purified by ultracentrifugation and injected into mice by the intramuscular route. In animal experiments, humoral and cellular immunoresponse were all triggered by H7N9 VLPs. High levels of specific antibodies and the isotypes of IgG were detected by ELISA. Anamnestic cellular immune responses were examined by detecting specific cytotoxic T cell for IFN-Υ production in ELISPOT assay. The hemagglutination-inhibition (HAI) against the homologous virus was more than 1:64, and cross-reactive HAI titers against the heterologous virus (H1N1 and H3N2) were more than 1:16. Moreover, VLPs immunized mice showed a rapid increase of neutralizing antibodies, with neutralizing antibody titers more than 1:8, which increased four-fold against PBS immunized mice in week four. By week six, the mice had high neutralization ability against the given strain and held a potent homologous virus neutralizing capacity. Thus, VLPs represent a potential strategy for the development of a safe and effective vaccine against novel avian influenza (H7N9) virus.

19 January 2018 in Luminescence
Verified
Journal Article
Closed access
PDF file
TWTian Wen
Tian Wen
CHChao Huang
Chao Huang
YZYi Zhang
Yi Zhang
XZXiaoyan Zeng
Xiaoyan Zeng
WLWendong Liu
Wendong Liu
YJYongjun Jiao
Yongjun Jiao